Eleven Straight Quarters of Mid-Single-Digit Growth — and an Activist Who Agrees That Isn't Enough. Initiating at Hold

Results vs. Consensus

Q1 FY2026 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Quality of Beat

Revenue: the +2.5% beat against consensus revenue overstates the operating quarter. Roughly $159M of the reported upside was favorable currency and $72M was "Other" revenue (divested-business transition agreements plus a $39M favorable adjustment to Italian payback accruals) — on an organic basis, growth of 4.8% sat exactly where management said it would, mid-range of the 4.5–5.0% guide. There is genuine quality in the composition, though: Cardiac Ablation at ~50% growth, Cardiac Rhythm & Heart Failure at +9.1% organic, and Diabetes at +7.9% are real franchises compounding above the company average. The problem is what they're offsetting — Specialty Therapies declined 2.7%, Surgical & Endoscopy grew just 2.3%, and the U.S. in aggregate grew only 3.5%.

Margins: the 80bp year-over-year decline in adjusted gross margin to 65.1% is the print's main operational blemish, and management's bridge deserves credit for candor: +30bp pricing, −70bp business mix (split roughly evenly between CAS — where lower-margin mapping-system capital is shipping ahead of higher-margin catheter pull-through — and Diabetes, where the Simplera sensor manufacturing ramp is early and inefficient), and a net −50bp from COGS programs being more than offset by the year-ago Affera manufacturing ramp comparison, plus +10bp FX. The important nuance: both mix headwinds are growth-driven and self-correcting — CAS capital placements precede catheter annuities, and Simplera scales with volume. This is margin pressure you want, but it is still margin pressure, and it lands while SG&A leverage (+170bp below revenue growth) is doing the heavy lifting to hold operating margin to −80bp.

EPS: +2% growth on +4.8% organic revenue growth is sub-par conversion for a company promising "natural P&L leverage." The gap is explained by the gross margin decline and deliberate R&D acceleration (+7.7%, about 100bp ahead of revenue growth) — a defensible trade, but one that pushes the earnings-leverage story into FY27, where management is now explicitly promising high-single-digit EPS growth. The $0.03 beat itself, as noted above, is mostly tax rate and FX. We'd characterize Q1 EPS as in-line-with-better-optics rather than a true beat.

Segment Performance

Portfolio Revenue Mix — Q1 FY2026

Cardiovascular — The Engine, and the Engine Inside the Engine

Cardiovascular grew 7.0% organic on top of a high-single-digit prior-year comparison, and the composition is what matters. Cardiac Rhythm & Heart Failure (+9.1% organic to $1,712M) is compounding on genuinely differentiated product: AURORA EV-ICD grew 83%, Micra leadless pacing grew 14% a decade into its lifecycle, and the 3830 conduction-system pacing lead grew 21%. Structural Heart & Aortic (+6.1% to $930M) is taking what management called its "fair share" of the international revenue freed by a competitor's market exit in TAVR, with Japan momentum building. Coronary & Peripheral Vascular (+2.9% to $643M) is the laggard, awaiting the Contego carotid-stent launch this quarter and the Liberant thrombectomy launch in H2.

The engine inside the engine is Cardiac Ablation Solutions at ~50% growth — low-70s% in the U.S. and Japan — on the strength of the PulseSelect anatomical catheter, the Sphere-9 focal catheter, and the Affera mapping system. Management said Affera grew nearly 60% sequentially.

"I've witnessed Affera and our competitors in action in several ablation cases. And I can tell you firsthand that the advantages that we're bringing to the market in terms of procedure time and ease of use are truly differentiated. Physician feedback and utilization levels of our equipment are phenomenal." — Geoff Martha, Chairman & CEO

Assessment: CAS is the single most valuable line in the Medtronic P&L right now. A ~50% grower with management guiding to faster growth next quarter, inside an $11B market expanding 25%+, with a supply ramp (mapper hiring, catheter capacity) that is the binding constraint rather than demand — that is the profile of a business that can move the consolidated growth rate by itself. The capital-before-catheters mix drag on gross margin is the tell that placements are running hot; catheter pull-through is the FY27 margin payoff.

Neuroscience — A Below-Trend Quarter With Self-Inflicted Timing

Neuroscience at +3.1% organic was the swing factor that kept the consolidated print at 4.8% rather than something faster. Cranial & Spinal Technologies grew 4.5% organic with the AiBLE ecosystem driving capital wins — Mazor, O-arm, Midas Rex, and StealthStation all grew double digits globally, and management claimed 5% U.S. core spine and 8% U.S. neurosurgery growth. Neuromodulation grew 8.6% organic on Inceptiv closed-loop pain stimulation (+10% global Pain Stim) and the BrainSense adaptive DBS launch. The drag was Specialty Therapies (−2.7%), where a deliberate Pelvic Health commercial reorganization ahead of this fall's tibial neurostimulation launch cost the quarter growth, and Neurovascular, still working through China volume-based procurement and a product recall comparison.

Assessment: the components here are stronger than the aggregate. AiBLE's ecosystem pull (health systems upgrading entire capital suites, not single devices) is a real moat in spine, and closed-loop sensing in both Pain Stim and DBS is a differentiated platform. But the segment needs Pelvic Health to actually deliver post-reorg and Neurovascular to lap its comps — both are H2 stories, which is the recurring theme of this print.

Medical Surgical — Stable Headwinds, Waiting on Hugo

MedSurg grew 2.4% organic. Advanced Energy grew high-single-digits with LigaSure winning share for the twelfth consecutive quarter, and emerging markets grew high-single-digits; those offset two "ongoing but stable" U.S. pressures — bariatric surgery softness and the procedural shift toward robotics, where Medtronic doesn't yet sell a U.S. system. The CE Mark for LigaSure on the Hugo robot matters strategically: it puts the world's most-used vessel-sealing technology (35M+ procedures) onto Medtronic's robotic platform ahead of the planned U.S. launch in H2 FY26, pending FDA approval of the urology indication filed earlier this calendar year.

Assessment: MedSurg is a 2% grower until Hugo changes the U.S. conversation, and management knows it. The robotics shift is currently a headwind precisely because Medtronic's surgical franchise is exposed to the laparoscopic stack being cannibalized; Hugo's U.S. arrival converts that from pure headwind to contested ground. We model no inflection before FY27 — first-generation robot launches are slow, reference-site-driven affairs.

Diabetes — Double-Digit International, a U.S. Air Pocket by Design

Diabetes grew 7.9% organic with a stark geographic split: +11.4% organic internationally, where the Simplera sensor is launched, versus +0.9% in the U.S., where patients and physicians are visibly waiting for next-generation CGM options. Management was explicit that this is a timing dynamic, not a demand problem: Simplera Sync production will double in Q2 versus Q1 and double again in H2 versus H1, and the Abbott-partnered Instinct sensor cleared a key approval gate in July with launch expected "in the coming months."

"We have this dynamic where patients are waiting for the new CGMs… we're going to be producing double what we made in Q1 and in the second half double what we're making in the first half." — Que Dallara, EVP & President, Diabetes

Assessment: we buy the timing explanation — the international growth rate where Simplera is available is the control group that proves the U.S. number is supply/product-cycle, not franchise decay. The more consequential development is corporate: the MiniMed separation timeline tightening to 15 months (see Key Topics) means this segment has roughly five more quarters inside Medtronic's reported organic growth. A Diabetes acceleration would flatter the consolidated number just as the company most needs the optics.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: management ran the call like an inflection announcement rather than an earnings review — the quarter's actual numbers were dispatched quickly so the airtime could go to the growth-driver calendar and the Elliott-aligned governance changes. The posture was confident and unusually forward-leaning, with repeated commitments to specific near-term milestones (CMS decision by October 8, CAS accelerating in Q2, sensors launching this fall) that create measurable accountability. The least convincing stretch was the repeated deferral of quantification — growth-driver contribution, long-term targets, and the new financial algorithm were all pushed to a mid-2026 Investor Day, which leaves a full year of "trust us" between promise and proof.

1. The Elliott Partnership: Governance as a Catalyst, and as a Confession

The defining disclosure of the day wasn't in the earnings release. Medtronic simultaneously announced that, following engagement with Elliott Management, it has appointed two new independent directors — John Groetelaars and Bill Jellison, both experienced medtech operators — and created two new Board committees: a Growth Committee overseeing portfolio management and capital allocation, and an Operating Committee overseeing efficiency in operations and the expense base. An Investor Day in mid-calendar 2026 will lay out the post-Diabetes strategy and new long-term financial targets.

"Medtronic is turning the page and we'll be entering a new period of greater revenue and earnings growth… we're putting the pieces together in place to translate that accelerating top line into a period of sustained outsized earnings growth." — Geoff Martha, Chairman & CEO

Management's framing was that the initiatives pre-dated Elliott's involvement and the activist simply endorses the direction: more M&A in high-growth categories (with Affera cited as the template), a portfolio reoriented toward higher weighted-average market growth, and increased reinvestment in R&D and growth-oriented SG&A — explicitly "not to the detriment of EPS," per the CFO.

Assessment: we read the Elliott arrangement as net positive but double-edged. Positive: two genuinely qualified medtech directors, a forcing function on capital allocation, and a public commitment to an algorithm-resetting Investor Day. Double-edged: a company eleven quarters into a consistent mid-single-digit run does not attract an activist, or restructure its board in response to one, if the market believes that run is adequate. The announcement is a confession that the status quo — 5% growth, ~2% EPS growth this quarter — was not creating value. The stock's decline on the news suggests the market priced the confession before the catalyst.

2. Cardiac Ablation: The $1B Increment Is Re-Committed, and Supply Is the Constraint

CAS grew ~50% with the U.S. and Japan both in the low-70s%. Management re-committed to adding ~$1B of incremental CAS revenue on the FY25 base "near term" — clarifying that the increment may straddle FY26 into FY27 but "won't be far" — and guided Q2 CAS growth to exceed Q1's rate with significant absolute sequential growth. The constraint is manufacturing and mapper headcount, both described as ramping on plan. The pipeline adds Sphere-360, a single-shot PFA catheter management called the most anticipated in the category, with a pivotal trial starting this calendar year.

"We've done meaningfully more [cases] in Japan, and I know we're the #1 there… the safety profile of our catheters, both the publicized safety of PulseSelect, but also Affera in our IDE trials… as PFA grows and becomes more ubiquitous, I think that's going to become a bigger kind of driver here in the U.S. as well and that plays to our favor." — Geoff Martha, Chairman & CEO

Assessment: the safety-led differentiation argument is more durable than a speed-led one — safety data compounds with volume while procedure-time advantages erode with competitor iteration. The supply-constrained framing cuts both ways: it validates demand but means execution risk now lives in Medtronic's own factories and hiring pipeline. We treat the $1B increment as the single most testable management commitment of FY26; it implies CAS sustains ~40–50%+ growth all year.

3. Renal Denervation: All the Dominoes Are Lined Up Before October 8

The CMS proposed National Coverage Determination for the Symplicity Spyral hypertension procedure is set to finalize on or before October 8, 2025. Management reported a record volume of public comments, "overwhelmingly positive," and — the under-appreciated development — the ACC and AHA issued updated guidelines recognizing renal denervation as a treatment option for hypertension, following similar European society moves. Medtronic is pre-positioning: hiring clinical specialists, market-development and health-economics managers, training interventional cardiologists, and helping hospitals stand up Symplicity service lines ahead of coverage.

"We think this is going to be — could be the biggest thing that we ever do." — Geoff Martha, Chairman & CEO

The cited population: roughly 18 million U.S. patients with uncontrolled hypertension despite drug availability — a market orders of magnitude larger than any device category Medtronic plays in today.

Assessment: "the biggest thing we ever do" is CEO-speak that deserves a discount, but the regulatory and clinical-society scaffolding now in place is objectively unusual — breakthrough designation, a proposed NCD with favorable framing, guideline inclusion on two continents, and a comment record. What no one knows is the slope: procedure economics, site-of-care buildout, and referral pathways from primary care to the cath lab will determine whether this is a $500M business in three years or five. The October 8 NCD is the gating catalyst; the language of the final determination (patient criteria, coverage-with-evidence requirements) will matter as much as the approval itself.

4. The MiniMed Separation Accelerates: 18 Months Becomes 15

The Diabetes separation — branded MiniMed — remains a two-step IPO-then-split, now expected to complete within 15 months (from 18 three months ago), with first investor engagements described as "very, very encouraging." Management reiterated the financial case: approximately 50bp of gross margin and 100bp of operating margin improvement for RemainCo upon separation, immediate EPS accretion "even with conservative valuations," and a sharpened focus on the core portfolio.

"It will also allow Medtronic to grow revenue and earnings faster without Diabetes than we do with it today." — Geoff Martha, Chairman & CEO

Assessment: the irony is that Diabetes grew 7.9% this quarter — above the company average — and is entering its strongest product cycle in a decade (two new sensors, a new pump, type 2 indication expansion). Medtronic is divesting a business at the moment its growth is inflecting, which is precisely when IPO valuation is maximized; that is good deal-craft. But the "grow faster without Diabetes" arithmetic depends on Diabetes's margin drag outweighing its growth contribution, and on management redeploying the focus and capital into CAS/Ardian-class opportunities rather than letting the WAMGR math quietly deteriorate. The 15-month clock also means FY26 reported numbers carry the separation's friction costs while FY27 gets the benefits.

5. The Gross Margin Bridge: Growth-Driven Mix Is Eating the COGS Program

The CFO gave an unusually clean four-part bridge for the 80bp adjusted gross margin decline: pricing +30bp (new-product launches plus contracting discipline), business mix −70bp (split roughly evenly between CAS capital-versus-catheter mix and the early Simplera manufacturing ramp), COGS efficiency programs net of inflation positive but more than offset by the Affera manufacturing ramp comparison (net −50bp), and FX +10bp.

Assessment: a +30bp pricing contribution is notable for a company that spent the last decade as a price-taker in commoditizing categories — it suggests the innovation mix (PFA, EV-ICD, adaptive DBS) is finally carrying pricing power. The mix headwinds are the acceptable cost of the two best growth stories in the portfolio. What we'll watch: management says both reverse "over time" as CAS scales catheters and Diabetes separates — if gross margin is still declining in Q4 FY26 after the NCD, the sensor ramps, and a year of COGS programs, the margin-expansion half of the FY27 high-single-digit EPS promise is in trouble.

6. The U.S. Problem: 3.5% Domestic Growth Against a 6.1% World

The least flattering cut of the quarter: U.S. revenue grew 3.5% against 6.1% organic internationally. Management attributed the gap to concentrated, identifiable U.S.-centric items — the Pelvic Health commercial reorganization, the Diabetes product-transition air pocket (U.S. +0.9% while international ran +11.4%), and U.S. Structural Heart at just +0.8% reported. The U.S. is also where the bariatric and robotics headwinds in Surgical concentrate.

Assessment: the explanations are individually credible and collectively uncomfortable — the highest-margin market is the slowest-growing, and the fix depends on the same H2 catalyst stack as everything else (Simplera/Instinct ramp, tibial launch, Ardian post-NCD, Hugo). The U.S. growth rate is our preferred single metric for tracking whether the acceleration narrative is real: it is where CAS is growing 72%, where the NCD applies, and where every launch lands first or fastest.

7. Tariffs: The Worst Case Comes Off the Table

Management removed the $350M worst-case tariff scenario for FY26 and improved the base case to approximately $185M (from ~$200M), crediting mitigation execution. The Q2 guide embeds ~$18M of tariff impact, implying a heavily back-half-weighted ~$167M remainder.

Assessment: the $15M improvement is minor; the scenario-removal is the signal — it converts an open-ended macro risk into a bounded, managed cost line. The back-half weighting of the remaining impact is worth flagging: it coincides with the quarters carrying the entire acceleration burden, so H2 EPS has both the revenue inflection and the tariff absorption to deliver simultaneously.

8. The Back-Half Architecture: Counting the Catalysts

Management's case for H2 acceleration rests on an unusually specific stack: CAS growth accelerating from ~50% with supply ramping; the Ardian U.S. launch ramping after the October 8 NCD; the tibial neurostimulation launch in Pelvic Health this fall; Simplera Sync and Instinct sensor launches with production doubling; Hugo's U.S. launch in H2 pending FDA approval; Contego carotid stenting launching this quarter and Liberant thrombectomy in H2; Neurovascular lapping China VBP and recall comps; and U.S. type 2 diabetes indication approval "in the coming months."

Assessment: eight datable catalysts in two quarters is either an embarrassment of riches or a concentration of execution risk, depending on your prior. Our prior, on a company with eleven quarters of unbroken mid-single-digit delivery and no recent track record of multi-launch quarters: respect the consistency, discount the simultaneity. If even half the stack lands on time, the Q4 FY26 organic print accelerates visibly; if launches slip a quarter each — the medtech base rate — FY26 ends at "approximately 5%" exactly as guided and the story rolls to FY27.

9. FY27: The High-Single-Digit EPS Commitment Hardens

The CFO reiterated — for the second consecutive quarter — the expectation of high-single-digit EPS growth in FY27, driven by accelerating revenue, improving business mix in CAS and Diabetes, and the financial benefits of the separation. Combined with the Investor Day promise of "new long-term financial targets," management is steadily pre-committing to a step-change in the earnings algorithm.

Assessment: this is the number the stock will ultimately trade on. MDT at ~16x forward EPS with ~4–5% EPS growth is fairly priced; MDT at 16x with durable high-single-digit EPS growth and a 3%+ yield is cheap. The FY27 commitment is the bridge between the two — and it now has an activist, two new committees, and an Investor Day attached to it as enforcement mechanisms.

Guidance & Outlook

The CFO's framing tied the raise to Q1 outperformance and the improved tariff assumption rather than any change in operating expectations — an honest characterization, since the organic growth guide didn't move. The CEO's qualitative framing carried the strategic weight: revenue growth "inflects in the back half," operating profit grows "materially faster than revenue" for the full year, and the company increases R&D and selling investment simultaneously. The unspoken arithmetic: holding ~5% organic for the year while Q1 printed 4.8% and Q2 is guided to 4.5–5.0% requires H2 organic growth in the mid-5s or better — the guide itself quietly embeds the acceleration thesis.

Implied Q-over-Q ramp: H1 at ~4.8% organic implies H2 must average ~5.2–5.5%+ to hold "approximately 5%" — modest on paper, but it must come while lapping progressively harder CAS comps, which means the new launches (Ardian, tibial, sensors, Hugo) must contribute measurably, not just symbolically.

Street at: consensus FY26 EPS sat at the very bottom of the new $5.60–$5.66 range entering the print; the raise effectively moves guidance midpoint ~1% above the Street, a small positive surprise that the market chose not to pay for on the day.

Guidance style: Medtronic under this CFO guides conservatively on EPS and precisely on organic revenue — eleven consecutive quarters inside the band is the empirical record. We treat the organic guide as reliable and the EPS guide as beatable by $0.03–$0.06 absent FX shocks.

Analyst Q&A Highlights

The 3.5% U.S. Growth Number, and Whether the Base Can Hold the Pipeline

The opening question went straight at the print's weak spot: the pipeline is visibly working — CAS grew 72% in the U.S. — yet total U.S. growth was 3.5% and U.S. Structural Heart grew about 1%. Management's response decomposed the U.S. softness into three named, temporary items — the Pelvic Health commercial reorganization, the Diabetes sensor-transition pause, and Neurovascular comps — and argued the incoming launch stack has an "outsized impact" on the U.S. specifically.

Q: "It's not showing up in the total U.S. growth. U.S. growth, 3.5% this quarter, 1% Structural Heart growth. Just want to hear your confidence — you talked about being confident in the ability to accelerate growth over FY '26, but how do you get confidence in kind of the base business still kind of growing mid-single digits so the pipeline can kind of be on top of that?"
— Travis Steed, BofA Securities

A: "Some of the pieces of the business that had a relatively slower growth in the first quarter were mostly U.S. impacting… in Pelvic Health, we made some changes in the commercial force… to prepare for the launch of tibial and that's primarily a U.S. impact… Diabetes grew very strongly. Outside of the U.S., we were up 11% in the international market. The U.S. was a bit slower and that's mostly a product topic… as this ramp-up occurs, we'll see those things start kicking in the U.S."
— Thierry Pieton, CFO

Assessment: the decomposition is credible — each named drag has a dated fix attached. But the exchange also established that the base business ex-drivers is growing below the company average in its most profitable market, which means the H2 acceleration must clear a lower launch bar than the headline numbers suggest. Management engaged the question directly rather than deflecting, which we credit.

What Two Board Committees Can Do That a Board Couldn't

A recurring line of questioning probed whether the new Growth and Operating committees are substance or ceremony. Management's answer emphasized three mechanics: deep medtech operating experience joining the board after a gap ("we had med tech experience in the past and recently not as much"), a higher frequency of board-management touchpoints including off-cycle sessions, and committee focus on the two specific value levers — portfolio growth and margin structure.

Q: "New Board committees, one focused on growth, one focused on operations. What can these committees do that you couldn't do before? What would success look like? And how long before investors start to see an impact?"
— Larry Biegelsen, Wells Fargo Securities

A: "We're bringing on these 2 new directors with deep med tech experience… We had med tech experience in the past and recently not as much… The amount of the intervals with management will be higher… A lot of off-cycle discussions that will help drive this."
— Geoff Martha, Chairman & CEO

Assessment: the candid admission that the board lacked recent medtech operating expertise is the most informative sentence in the exchange — it implicitly validates the activist's diagnosis. Committee structures don't create value, but director quality and cadence can change capital-allocation outcomes at the margin. Watch the first Growth Committee-era M&A deal for evidence of changed behavior.

Pinning Down the $1B CAS Increment

Asked directly whether the ~$2B annualized CAS revenue ambition is achievable within FY26, management re-anchored the commitment — $1B incremental over the FY25 base, "near term" — and acknowledged it likely straddles into FY27 while emphasizing nothing has slipped.

Q: "Is that $2 billion that you've talked about in annual CAS sales now squarely on the table for fiscal '26? Or what reservations would you have about committing to that?"
— Mike Kratky, Leerink Partners

A: "When I said that, we're sticking to that. Nothing's changed… it's another $1 billion on top of our FY '25 base, right? So that's what we're anchored on… I think it will go into FY '27, but it won't be far. So that's on track."
— Geoff Martha, Chairman & CEO

Assessment: a precise commitment, precisely maintained, with the timing honestly hedged by one or two quarters. This is the most auditable promise in the Medtronic story — CAS revenue is disclosed well enough each quarter to track the increment in real time. Management is choosing accountability here, which raises our confidence in the number.

Elliott: Continuation or Wholesale Change?

The strategic question underneath the governance news: is this an acceleration of the existing portfolio-optimization strategy, or the opening of something bigger — capital structure, the dividend, company scale all on the table? Management's answer leaned heavily toward continuation-with-amplification: more M&A in high-growth categories, reorienting the portfolio toward higher weighted-average market growth with the Diabetes deal as proof point, and investing more behind "transformational growth drivers" — while conspicuously not ruling anything out.

Q: "Is this something where maybe the size of the company, the dividend, the capital allocation might be up for a discussion how to create more EPS growth? I'm just trying to understand how much of this is more a continuation, Geoff, of your strategy since you became CEO?… versus maybe evaluating something more of a wholesale change."
— Robbie Marcus, JPMorgan

A: "It's all about value creation and some bold decisions around a couple of areas. One is more M&A… A reinvigorated laser focus on the portfolio to reorient the whole portfolio between M&A and any kind of portfolio moves towards higher growth. So increase our WAMGR. Diabetes deal is a good proof point, but there's other opportunities we can look at here… And then the second is investing more in the company."
— Geoff Martha, Chairman & CEO

Assessment: "there's other opportunities we can look at here" is the live wire — it signals further divestitures beyond Diabetes are on the Growth Committee's table. The dividend question went unanswered, which for a 48-year dividend grower is itself an answer: no change contemplated. The wholesale-change scenario (a breakup) was neither embraced nor denied; we assign it low probability before the Investor Day.

Quantifying the Growth Drivers — the Question Management Wouldn't Answer

The most analytically important exchange of the call: asked to translate the growth-driver excitement into basis points of consolidated growth over the next 12–24 months, management explicitly declined, deferring all quantification to the mid-2026 Investor Day while offering directional magnitude (CAS's $1B increment, Ardian as a "secular change") and the assurance that the drivers are incremental to, not substitutes for, base-business growth.

Q: "Try to square what these can mean on an annual basis to sort of overall Medtronic portfolio growth… maybe help us walk through a cadence of 25 or 50 basis points over the next 12 months. Is it another 25 or 50 basis points maybe in '27?"
— Matt Miksic, Barclays

A: "I'm not going to give you very specific targets until we get to that point because that will be the whole purpose of that discussion… You'll start seeing the signs in the second half, and then we'll show the new framework when we talk to you in the mid of '26."
— Thierry Pieton, CFO

Assessment: a rational deferral — you don't pre-release your Investor Day — but it leaves a four-quarter quantification vacuum during exactly the period when the stock needs a reason to re-rate. Until mid-2026, the only scoreboard is the reported organic growth rate itself.

How Big Is Renal Denervation, Really?

Asked for the best-case framing of the hypertension opportunity and where it ranks among the growth drivers, management stacked the regulatory dominoes (record comment volume on the proposed NCD, ACC/AHA guideline inclusion, hospital demand for service-line buildout) and then went further than expected on magnitude.

Q: "Maybe just frame for us what you would view as the best case outcome in terms of the targeted population in uncontrolled hypertension… Can this be a multibillion dollar product category over the next few years?"
— Anthony Petrone, Mizuho

A: "All the dominoes are falling. The puzzle pieces snapping into place that this is going to be a massive market… I still think Ardian has a chance to even be bigger [than CAS]… we think this is going to be — could be the biggest thing that we ever do."
— Geoff Martha, Chairman & CEO

Assessment: "bigger than CAS" is an extraordinary claim for a therapy with essentially zero current U.S. reimbursed volume. The 18M uncontrolled-hypertension population makes the TAM math defensible in theory; the unknowns are referral-pathway friction and the final NCD's patient criteria. We model Ardian as optionality, not base case, until at least two quarters of post-NCD procedure data exist.

The Diabetes U.S. Slowdown: Disruption or Timing?

A three-part question pressed on whether the U.S. Diabetes deceleration reflected separation-related disruption, how to model the re-ramp, and what remains for the Instinct launch. Management's answer — delivered by the Diabetes president — was unambiguous: demand exists, patients are waiting for the new sensors, production is doubling sequentially, and Instinct's key approval gate cleared in July.

Q: "I just want to maybe check and make sure there hasn't been disruption that's leading to a slowdown. And then second, just to set expectations in terms of how we… should be thinking about the ramp from here in the U.S. Diabetes business?"
— Josh Jennings, TD Securities

A: "It's really a matter of timing in the first half… the demand is absolutely there. So we have this dynamic where patients are waiting for the new CGMs… we're going to be producing double what we made in Q1 and in the second half double what we're making in the first half… we'll be in a very strong position to launch [Instinct] in the coming months."
— Que Dallara, EVP & President, Diabetes

Assessment: the international control group (+11.4% organic where Simplera ships) supports the timing thesis. The risk is competitive: every quarter a U.S. patient waits for a Medtronic sensor is a quarter a competing CGM ecosystem can intercept them. The production-doubling cadence is specific enough to audit in Q2 and Q3 international/U.S. splits.

What They're NOT Saying

1. No organic revenue guide raise despite the "acceleration" drumbeat: the entire call was choreographed around inflection, yet the FY26 organic guide stayed at ~5% — the same number set in May. Management is selling acceleration rhetorically while underwriting continuity numerically. The conservative read is prudence; the skeptical read is that the H2 launch stack isn't yet bankable.
2. Elliott's stake size and terms were never disclosed: no 13D has surfaced, no standstill terms were described, and the word "agreement" was carefully avoided in favor of "partnership" and "engagement." The durability and demands of the arrangement are unknowable from the outside.
3. No Hugo revenue, placement, or installed-base figures: "over 30 countries" and "tens of thousands of procedures" are directionally encouraging and financially opaque — now several years into the international launch. The continued absence of numbers implies the base remains immaterial; the U.S. launch will start from effectively zero.
4. MiniMed valuation expectations went unstated: "immediately EPS accretive even with conservative valuations" implies a valuation framework exists internally, but no range, no proceeds expectation, and no use-of-proceeds plan (buyback? M&A war chest?) was offered for the largest portfolio move in company history.
5. Share repurchases nearly stopped: $123M of buyback this quarter versus $2.49B in the prior-year quarter — an order-of-magnitude pullback, unmentioned in prepared remarks, while $910M went to dividends and debt was repaid. Capital is visibly being held back for something; whether that's tariff caution, M&A capacity, or separation mechanics was not addressed.
6. U.S. Structural Heart at +0.8% got one passing mention: the international TAVR share story (competitor exit, Japan momentum) got airtime; the near-flat U.S. TAVR number — in the segment's largest market, against an entrenched leader — did not. Competitive dynamics in U.S. TAVR deserve scrutiny next quarter.
7. The FY26 EPS raise is smaller than the tariff improvement: tariffs improved by ~$15M-plus versus the prior base case (and up to $165M versus the worst case), while the EPS guide rose $0.08 at the midpoint (~$100M pre-tax equivalent). The underlying operating raise net of tariffs and tax is thinner than the headline suggests.

Market Reaction

• Pre-print setup: MDT closed Monday August 18 at $92.81, up roughly 16% year-to-date and sitting near the top of its trailing 12-month range — a stock that had already quietly re-rated on PFA momentum and separation anticipation, leaving little cushion for an in-line print.
• Day-of session: the stock gapped down ~5.4% at the open to $87.84 despite the EPS beat, the guidance raise, and the Elliott announcements, then recovered roughly half the gap intraday to close at $89.90, −3.1%, on 19.6M shares — roughly 3x recent average volume. The intraday recovery pattern suggests the opening flush was positioning-driven and the dip found fundamental buyers.

The reaction is best read as the market grading the quarter's texture rather than its headlines. The headlines were uniformly positive — beat, raise, activist-blessed governance refresh. The texture was an in-line organic quarter with declining gross margin, 3.5% U.S. growth, a tax-aided EPS beat, and an acceleration story whose entire evidence base sits in future quarters. A stock up 16% YTD into the print had already paid for the headlines; the texture is what got marked.

There is also an Elliott-specific dynamic worth naming: governance announcements of this kind reliably produce a "now what?" trade. The investors who wanted activist involvement got their catalyst and took profits; the investors who must now underwrite the turnaround want evidence the committees change anything. Between catalyst delivery and proof of change, the stock is in show-me territory — which is precisely where our rating sits.

Street Perspective

Debate: Is Elliott's Arrival a Catalyst or a Warning?

Bull view: a sophisticated activist with a medtech track record validated the asset quality, secured real governance change without a proxy fight, and created a dated forcing function (the mid-2026 Investor Day) for a new financial algorithm — the classic setup for a multi-year re-rating in an under-earning large cap.

Bear view: activists target companies where management has under-delivered for years, and constructive settlements without board control rarely force hard choices; the committees add process, not progress, and the 11-quarter "consistency" record the company celebrates is precisely the 5%-growth treadmill the stock has been de-rated for.

Our take: the bear framing of the past is accurate and the bull framing of the future is plausible — which is what makes this a Hold rather than either conviction call. The two director appointments are genuinely high-quality, and the Investor Day creates accountability. But the value-creation mechanism still runs entirely through operational delivery that hasn't happened yet.

Debate: Will the Back-Half Acceleration Actually Arrive?

Bull view: the catalyst stack is unusually concrete — a dated CMS decision, named product launches with cleared approval gates, a CAS franchise already compounding at 50% with supply as the only constraint — and the guide only requires H2 organic growth in the mid-5s, a low bar for eight simultaneous catalysts.

Bear view: medtech launch timelines slip as a base rate, the company has trained the market for years to expect "acceleration next half"; U.S. growth of 3.5% shows the base business is softer than the consolidated print implies, and harder CAS comps arrive exactly when the new launches must hand off.

Our take: we lean modestly toward the bull on direction (the CAS and sensor-ramp components are visible and near-certain) and toward the bear on magnitude — the difference between 5.2% and 6% H2 organic growth is the difference between an in-line year and a re-rating, and we can't underwrite the higher number from one quarter of evidence. Q2's U.S. growth rate and the October 8 NCD language are the next two data points that matter.

Debate: Does the MiniMed Separation Create or Transfer Value?

Bull view: RemainCo gets ~50bp of gross margin, ~100bp of operating margin, a higher weighted-average market growth rate, and management focus on its best franchises — while the IPO monetizes Diabetes at peak product-cycle valuation. Both sides of the split win.

Bear view: Medtronic is divesting its third-fastest-growing segment (+7.9% this quarter, accelerating) right as a decade of CGM/pump investment pays off — selling the inflection to buy margin optics, and shrinking the revenue base while promising faster growth from what remains.

Our take: separation logic is sound for this company specifically — Diabetes consumes disproportionate capital and management bandwidth for a consumer-electronics-cadence business Medtronic has historically run poorly. The bull case requires the freed capital to be redeployed into CAS/Ardian-class assets rather than returned reflexively; the new Growth Committee's first moves will tell us which world we're in.

Model Update Needed

Valuation impact: at $89.90, MDT trades at ~16.0x the new FY26 EPS midpoint with a ~3.2% dividend yield backed by 48 consecutive years of increases. That multiple embeds the 5%-growth treadmill, not the acceleration. Each 100bp of durable organic growth improvement plausibly carries 2–3 turns of multiple expansion in medtech comps; the FY27 high-single-digit EPS commitment, if validated, supports a $105–115 framework. We are not paying for that until the evidence arrives — fair value today sits in the low-to-mid $90s, roughly where the stock closed before the print.

Thesis Scorecard Post-Earnings

Overall: thesis intact on both sides — which is the definition of a Hold. The growth assets are performing above expectations; the consolidated financials are not yet showing it.

Action: initiate coverage at Hold. Watch items for Q2 (November 18): U.S. organic growth rate, CAS growth versus the "faster than Q1" commitment, the October 8 NCD language, and Simplera/Instinct U.S. launch execution. Two of four landing bullishly moves the rating debate; all four would settle it.